跳至主要内容
临床试验/EUCTR2017-003466-28-IT
EUCTR2017-003466-28-IT进行中(未招募)1 期

A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancer

DAIICHI SANKYO INC.0 个研究点目标入组 78 人开始时间: 2021年1月14日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
78

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Pathologically documented unresectable, recurrent, or metastatic
  • colorectal adenocarcinoma. Until sponsor's notification to the study
  • sites, subject must be a (BRAF) wild-type cancer.
  • 2. Received at least 2 prior regimens of standard treatment.
  • 3. Has measurable disease assessed by the investigator based on RECIST
  • version 1.1.
  • 4. Has an Eastern Cooperative Oncology Group Performance Status (ECOG
  • PS) of 0 to 1
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • 1. Medical history of myocardial infarction within 6 months before enrollment (study treatment), symptomatic congestive heart failure
  • 2 Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
  • 3. Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy

研究者

相似试验

进行中(未招募)
1 期
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancerHuman epidermal growth factor receptor 2 (HER2)- expressing advanced colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10010029 Term: Colorectal cancer NOS System Organ Class: 100000004864
EUCTR2017-003466-28-GBDaiichi Sankyo Inc.90
进行中(未招募)
1 期
A Phase 2, multicenter, open-label study of DS-8201a in subjects with HER2-expressing advanced colorectal cancerHuman epidermal growth factor receptor 2 (HER2)- expressing advanced colorectal cancerMedDRA version: 20.0Level: LLTClassification code 10010029Term: Colorectal cancer NOSSystem Organ Class: 100000004864
EUCTR2017-003466-28-ESDaiichi Sankyo Inc.78
进行中(未招募)
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.
EUCTR2016-004986-18-ESDaiichi Sankyo Inc.230
进行中(未招募)
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.nresectable/metastatic breast cancer with HER2 positive expressionMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864
EUCTR2016-004986-18-ITDAIICHI SANKYO INC.253
进行中(未招募)
1 期
A Phase 2 study of DS-8201a for HER2-Positive breast cancer that has either spread and/or cannot be treated with surgery and is resistant or non-responsive to T-DM1 treatment.
EUCTR2016-004986-18-FRDaiichi Sankyo Inc.253
A Phase 2, multicenter, open-label study of DS-8201a... | 临床试验